Mirum Pharmaceuticals, Inc. (MIRM) Tops Q2 EPS by 21c

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q2 EPS of ($0.12), $0.21 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $127.78 million versus the consensus estimate of $107.36 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
• Trump plans to request Supreme Court rehearing on birthright citizenship
• Thunder Mountain Gold to issue shares to settle $1.1M in debt